Published in Proc Natl Acad Sci U S A on November 15, 2005
Quinacrine Treatment in Patients With Androgen-Independent Prostate Cancer | NCT00417274
Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer (2009) 5.12
An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science (2008) 4.89
The expanding universe of p53 targets. Nat Rev Cancer (2009) 3.49
Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proc Natl Acad Sci U S A (2010) 3.00
Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta (2010) 2.55
Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle (2009) 2.43
Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet (2008) 1.96
Pathologies associated with the p53 response. Cold Spring Harb Perspect Biol (2010) 1.40
Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro Oncol (2010) 1.33
Inflammation and p53: A Tale of Two Stresses. Genes Cancer (2011) 1.27
Mycoplasma infection suppresses p53, activates NF-kappaB and cooperates with oncogenic Ras in rodent fibroblast transformation. Oncogene (2008) 1.20
Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem (2010) 1.10
An NF-kappaB and slug regulatory loop active in early vertebrate mesoderm. PLoS One (2006) 1.09
Current and potential inflammation targeted therapies in head and neck cancer. Curr Opin Pharmacol (2009) 1.08
Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. PLoS One (2010) 1.04
New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents. Future Oncol (2009) 1.04
Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. J Control Release (2010) 1.03
Dysregulation of the mTOR pathway in p53-deficient mice. Cancer Biol Ther (2013) 1.02
Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers. Cell Commun Signal (2011) 0.99
Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1. Mol Cancer (2010) 0.98
Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts. Neoplasia (2013) 0.98
p53 gene in treatment of hepatic carcinoma: status quo. World J Gastroenterol (2007) 0.95
Novel HIV-1 therapeutics through targeting altered host cell pathways. Expert Opin Biol Ther (2009) 0.94
LMP1-augmented kappa intron enhancer activity contributes to upregulation expression of Ig kappa light chain via NF-kappaB and AP-1 pathways in nasopharyngeal carcinoma cells. Mol Cancer (2009) 0.93
A novel strategy for inducing the antitumor effects of triterpenoid compounds: blocking the protumoral functions of tumor-associated macrophages via STAT3 inhibition. Biomed Res Int (2014) 0.92
Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism. J Inflamm (Lond) (2014) 0.92
Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state. Cancer Res (2011) 0.90
Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB. Cancer Prev Res (Phila) (2009) 0.90
TAT-mediated intracellular delivery of NPM-derived peptide induces apoptosis in leukemic cells and suppresses leukemogenesis in mice. Blood (2008) 0.89
TRIM8 anti-proliferative action against chemo-resistant renal cell carcinoma. Oncotarget (2014) 0.89
Small-molecule inhibitor which reactivates p53 in human T-cell leukemia virus type 1-transformed cells. J Virol (2008) 0.88
FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-kappaB. Proc Natl Acad Sci U S A (2011) 0.88
A novel mechanism of crosstalk between the p53 and NFκB pathways: MDM2 binds and inhibits p65RelA. Cell Cycle (2013) 0.88
Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent. Anticancer Res (2009) 0.87
Drug 9AA reactivates p21/Waf1 and Inhibits HIV-1 progeny formation. Virol J (2008) 0.87
The apoptosis repressor with a CARD domain (ARC) gene is a direct hypoxia-inducible factor 1 target gene and promotes survival and proliferation of VHL-deficient renal cancer cells. Mol Cell Biol (2013) 0.87
Loss of IKKbeta activity increases p53 stability and p21 expression leading to cell cycle arrest and apoptosis. J Cell Mol Med (2009) 0.87
Inhibition of human parainfluenza virus type 3 infection by novel small molecules. Antiviral Res (2007) 0.87
EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells. Proc Natl Acad Sci U S A (2014) 0.86
Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells. Mol Cancer (2013) 0.86
Combination of NTP with cetuximab inhibited invasion/migration of cetuximab-resistant OSCC cells: Involvement of NF-κB signaling. Sci Rep (2015) 0.85
p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma. Cell Death Dis (2015) 0.84
Tumor miR-125b predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection. Cancer Sci (2014) 0.83
Dynamic aberrant NF-κB spurs tumorigenesis: a new model encompassing the microenvironment. Cytokine Growth Factor Rev (2015) 0.83
Inhibition of encephalomyocarditis virus and poliovirus replication by quinacrine: implications for the design and discovery of novel antiviral drugs. J Virol (2010) 0.83
Biological clues to potent DNA-damaging activities in food and flavoring. Food Chem Toxicol (2013) 0.82
Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer. Mol Cancer Ther (2014) 0.82
NF-κB pathway in colitis-associated cancers. Transl Gastrointest Cancer (2013) 0.81
The restrained expression of NF-kB in renal tissue ameliorates folic acid induced acute kidney injury in mice. PLoS One (2015) 0.81
Modifying radiation damage. Curr Drug Targets (2010) 0.81
EBV-encoded LMP1 upregulates Igκ 3'enhancer activity and Igκ expression in nasopharyngeal cancer cells by activating the Ets-1 through ERKs signaling. PLoS One (2012) 0.81
Peptides genetically selected for NF-κB activation cooperate with oncogene Ras and model carcinogenic role of inflammation. Proc Natl Acad Sci U S A (2014) 0.81
Identification of inhibitors of ovarian cancer stem-like cells by high-throughput screening. J Ovarian Res (2012) 0.80
Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models. Cancer Res (2016) 0.80
Anti-cancer activity of a novel small molecule compound that simultaneously activates p53 and inhibits NF-κB signaling. PLoS One (2012) 0.80
Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia. Blood Cancer J (2015) 0.80
9-Aminoacridine inhibition of HIV-1 Tat dependent transcription. Virol J (2009) 0.80
Quinacrine impairs enterovirus 71 RNA replication by preventing binding of polypyrimidine-tract binding protein with internal ribosome entry sites. PLoS One (2013) 0.79
Quinacrine Inhibits Cell Growth and Induces Apoptosis in Human Gastric Cancer Cell Line SGC-7901. Curr Ther Res Clin Exp (2012) 0.79
Quinacrine promotes autophagic cell death and chemosensitivity in ovarian cancer and attenuates tumor growth. Oncotarget (2015) 0.79
Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system. Antiviral Res (2011) 0.79
Signaling of chloroquine-induced stress in the yeast Saccharomyces cerevisiae requires the Hog1 and Slt2 mitogen-activated protein kinase pathways. Antimicrob Agents Chemother (2014) 0.78
p53 regulates the transcription of the anti-inflammatory molecule developmental endothelial locus-1 (Del-1). Oncotarget (2013) 0.78
Oxidative pentose phosphate pathway inhibition is a key determinant of antimalarial induced cancer cell death. Oncogene (2015) 0.77
Repurposing the anti-malarial drug, quinacrine: new anti-colitis properties. Oncotarget (2016) 0.77
Combination of 9-aminoacridine with Campath-1H provides effective therapy for a murine model of adult T-cell leukemia. Retrovirology (2014) 0.77
In silico screening reveals structurally diverse, nanomolar inhibitors of NQO2 that are functionally active in cells and can modulate NF-κB signaling. Mol Cancer Ther (2011) 0.76
Small-molecule xenomycins inhibit all stages of the Plasmodium life cycle. Antimicrob Agents Chemother (2014) 0.76
MicroRNA-375 Is Induced in Cisplatin Nephrotoxicity to Repress Hepatocyte Nuclear Factor 1-β. J Biol Chem (2017) 0.75
Reducing radiation-induced gastrointestinal toxicity - the role of the PHD/HIF axis. J Clin Invest (2016) 0.75
VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma. Oncotarget (2016) 0.75
Gene regulatory network underlying the immortalization of epithelial cells. BMC Syst Biol (2017) 0.75
Protective effect of quinacrine against glycerol-induced acute kidney injury in rats. BMC Nephrol (2017) 0.75
Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade. Oncotarget (2017) 0.75
Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53. Mol Cancer Ther (2016) 0.75
9-AAA inhibits growth and induces apoptosis in human melanoma A375 and rat prostate adenocarcinoma AT-2 and Mat-LyLu cell lines but does not affect the growth and viability of normal fibroblasts. Oncol Lett (2016) 0.75
Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. Neuro Oncol (2017) 0.75
Preclinical Validation of a Single-Treatment Infusion Modality That Can Eradicate Extremity Melanomas. Cancer Res (2016) 0.75
Quinacrine for extremity melanoma in a mouse model of isolated limb perfusion (ILP). Surg Today (2014) 0.75
Potential malignant transformation in the gastric mucosa of immunodeficient mice with persistent Mycoplasma penetrans infection. PLoS One (2017) 0.75
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
The p53 pathway. J Pathol (1999) 6.79
The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell (2002) 5.84
Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci (2005) 5.01
Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature (2003) 4.55
IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature (2005) 4.31
Transcriptional cross talk between NF-kappaB and p53. Mol Cell Biol (1999) 3.40
NF-kappaB as a therapeutic target in cancer. Trends Mol Med (2002) 3.08
The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett (2004) 2.41
Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol (2004) 2.35
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ (2004) 2.23
IKKalpha, IKKbeta, and NEMO/IKKgamma are each required for the NF-kappa B-mediated inflammatory response program. J Biol Chem (2002) 1.94
Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I kappa B-alpha. J Biol Chem (1996) 1.78
Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. Oncogene (2003) 1.61
p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res (2004) 1.47
Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev (2003) 1.46
Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma. Carcinogenesis (2003) 1.37
Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene (2001) 1.30
Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II. J Biol Chem (1989) 1.27
Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies. Cancer (2004) 1.24
Capsaicin exhibits anti-inflammatory property by inhibiting IkB-a degradation in LPS-stimulated peritoneal macrophages. Cell Signal (2003) 1.13
High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. Carcinogenesis (2002) 1.13
NF-kappaB inhibits transcription of the H(+)-K(+)-ATPase alpha(2)-subunit gene: role of histone deacetylases. Am J Physiol Renal Physiol (2002) 1.12
Loss of nuclear factor-kappaB is tumor promoting but does not substitute for loss of p53. Cancer Res (2004) 1.09
The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum (1989) 1.03
Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer (2003) 1.03
Dominant negative form of signal-regulatory protein-alpha (SIRPalpha /SHPS-1) inhibits tumor necrosis factor-mediated apoptosis by activation of NF-kappa B. J Biol Chem (2002) 1.00
Setting the stage for transformation: HTLV-1 Tax inhibition of p53 function. Front Biosci (2005) 0.89
Effect of quinacrine, a phospholipase A2 inhibitor on stress and chemically induced gastroduodenal ulcers. Digestion (1997) 0.84
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov (2007) 6.33
An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science (2008) 4.89
Complex modulation of cell type-specific signaling in response to type I interferons. Immunity (2006) 4.48
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci U S A (2010) 3.81
SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol (2003) 3.69
Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol (2002) 3.64
Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev (2007) 3.57
Longitudinal analysis of neural network development in preterm infants. Cereb Cortex (2010) 3.47
Weak p53 permits senescence during cell cycle arrest. Cell Cycle (2010) 3.33
The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) (2010) 3.27
Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res (2005) 3.10
Pseudo-DNA damage response in senescent cells. Cell Cycle (2009) 2.93
Pulmonary bioassay studies with nanoscale and fine-quartz particles in rats: toxicity is not dependent upon particle size but on surface characteristics. Toxicol Sci (2006) 2.57
Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability. Oncogene (2002) 2.52
Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol (2006) 2.47
Pulmonary toxicity study in rats with three forms of ultrafine-TiO2 particles: differential responses related to surface properties. Toxicology (2006) 2.47
A large set of Finnish affected sibling pair families with type 2 diabetes suggests susceptibility loci on chromosomes 6, 11, and 14. Diabetes (2004) 2.46
Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle (2009) 2.43
BMAL1-dependent circadian oscillation of nuclear CLOCK: posttranslational events induced by dimerization of transcriptional activators of the mammalian clock system. Genes Dev (2003) 2.37
Pulmonary instillation studies with nanoscale TiO2 rods and dots in rats: toxicity is not dependent upon particle size and surface area. Toxicol Sci (2006) 2.34
Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene (2004) 2.34
Roles of unphosphorylated STATs in signaling. Cell Res (2008) 2.27
Cellular quiescence caused by the Mdm2 inhibitor nutlin-3A. Cell Cycle (2009) 2.22
Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem (2001) 2.21
IRF-3-dependent, NFkappa B- and JNK-independent activation of the 561 and IFN-beta genes in response to double-stranded RNA. Proc Natl Acad Sci U S A (2002) 2.20
Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci U S A (2009) 2.10
Structural basis of TLR5-flagellin recognition and signaling. Science (2012) 2.10
Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc Natl Acad Sci U S A (2010) 2.06
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell (2011) 2.04
Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT. Sci Transl Med (2011) 2.03
Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res (2006) 2.03
NFkappaB-dependent signaling pathways. Exp Hematol (2002) 1.98
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
p53 is a suppressor of inflammatory response in mice. FASEB J (2005) 1.91
Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. Proc Natl Acad Sci U S A (2005) 1.91
Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem (2004) 1.88
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol (2008) 1.87
Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci U S A (2012) 1.83
The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc Natl Acad Sci U S A (2003) 1.80
Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. Aging (Albany NY) (2012) 1.79
Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci U S A (2009) 1.78
Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. ACS Chem Biol (2011) 1.77
Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget (2011) 1.73
Proteolytic cleavage of the p65-RelA subunit of NF-kappaB during poliovirus infection. J Biol Chem (2005) 1.71
p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc Natl Acad Sci U S A (2012) 1.71
Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer. Cell Cycle (2009) 1.66
A purine nucleotide biosynthesis enzyme guanosine monophosphate reductase is a suppressor of melanoma invasion. Cell Rep (2013) 1.58
A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev (2006) 1.58
Keratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells. Blood (2007) 1.51
Transposon-based mutagenesis identifies short RIP1 as an activator of NFkappaB. Cell Cycle (2008) 1.49
Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev (2002) 1.49
Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFkappaB. Proc Natl Acad Sci U S A (2009) 1.49
The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J Interferon Cytokine Res (2010) 1.48
Apoptosis inhibitor as a suppressor of tumor progression: expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor. Cancer Biol Ther (2002) 1.48
p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res (2004) 1.47
New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis. Aging (Albany NY) (2012) 1.47
Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci U S A (2004) 1.45
Dose-dependent cross-talk between the transforming growth factor-beta and interleukin-1 signaling pathways. Proc Natl Acad Sci U S A (2007) 1.42
Interleukin-1 receptor-associated kinase 2 is critical for lipopolysaccharide-mediated post-transcriptional control. J Biol Chem (2009) 1.42
p130/p107/p105Rb-dependent transcriptional repression during DNA-damage-induced cell-cycle exit at G2. J Cell Sci (2005) 1.39
Secretion of cytokines and growth factors as a general cause of constitutive NFkappaB activation in cancer. Oncogene (2004) 1.38
Identification of a human NF-kappaB-activating protein, TAB3. Proc Natl Acad Sci U S A (2004) 1.37
HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res (2004) 1.35
Cytokine overexpression and constitutive NFkappaB in cancer. Cell Cycle (2004) 1.34
G2 arrest in response to topoisomerase II inhibitors: the role of p53. Cancer Res (2003) 1.31
Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Res (2009) 1.31
Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease. PLoS Pathog (2012) 1.30
Core circadian protein CLOCK is a positive regulator of NF-κB-mediated transcription. Proc Natl Acad Sci U S A (2012) 1.28
Synthetic mRNA splicing modulator compounds with in vivo antitumor activity. J Med Chem (2009) 1.28
A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res (2011) 1.27
IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J (2013) 1.26
Major differences in the responses of primary human leukocyte subsets to IFN-beta. J Immunol (2010) 1.26
Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice. Cancer Res (2006) 1.23
Association of Mycoplasma hominis infection with prostate cancer. Oncotarget (2011) 1.19
Cancer resistance in the blind mole rat is mediated by concerted necrotic cell death mechanism. Proc Natl Acad Sci U S A (2012) 1.18
Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci U S A (2007) 1.18
Antitumor compounds based on a natural product consensus pharmacophore. J Med Chem (2008) 1.17
PRMT5 dimethylates R30 of the p65 subunit to activate NF-κB. Proc Natl Acad Sci U S A (2013) 1.17
Mutagenesis by reversible promoter insertion to study the activation of NF-kappaB. Proc Natl Acad Sci U S A (2005) 1.17
Down-regulation of p53 by double-stranded RNA modulates the antiviral response. J Virol (2005) 1.17
Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney. Am J Surg Pathol (2010) 1.16
Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proc Natl Acad Sci U S A (2013) 1.16
Mutant human cells with constitutive activation of NF-kappaB. Proc Natl Acad Sci U S A (2003) 1.14